ライフサイエンスコーパス: blood count

1 quantified via body weight loss and complete blood count.

2 as outpatients with at least 1 differential blood count.

3 nalyzer and reported as part of the complete blood count.

4 clone did not correlate with improvement in blood count.

5 d no increase or decrease in the markers and blood count.

6 gingival index (GI); 5) CRP; and 6) complete blood count.

7 eye with no evidence of leucocytosis on the blood count.

8 nal ICUS (CCUS) and MDS as were mean age and blood counts.

9 1) in sputum and a 100% decrease (day 28) in blood counts.

10 8) in sputum and a 100% decrease (day 84) in blood counts.

11 n mimetic eltrombopag (Promacta) can improve blood counts.

12 and proteomics of brushings, and peripheral blood counts.

13 o in patients with normal or increased white blood counts.

14 ence in CD4, CD8, natural killer, and B-cell blood counts.

15 logic response at 6 months, as determined by blood counts.

16 ed hematopoiesis resulting in low peripheral blood counts.

17 h rapamycin significantly normalizes the low blood counts.

18 (77%) were detected by clinical symptoms or blood counts.

19 n underlies variation in baseline peripheral blood counts.

20 r therapeutic approach to improve peripheral blood counts.

21 l consumption all had significant effects on blood counts.

22 in transfusion independence and near-normal blood counts.

23 een dysregulated Janus kinase 2 and elevated blood counts.

24 econstitution was assessed by doing complete blood counts.

25 d with previous chemotherapy than peripheral blood counts.

26 other than a mild, reversible suppression of blood counts.

27 entified in individuals with normal complete blood counts.

28 irst year of life, and had normal peripheral blood counts.

29 ion studies, serum chemistries, and complete blood counts.

30 dysplastic syndrome in the setting of stable blood counts.

31 uding overall survival (OS) and longitudinal blood counts.

32 (EG), leading to dysregulation in neutrophil blood counts.

33 d and bone marrow cells, as well as improved blood counts.

34 y diagnosed ALL (1 to 9 years old with white blood count 50 000/mm3 or more, or 10 years of age or ol

35 sly clear peripheral blasts (89%), normalize blood counts (74%), and maintain a complete remission (6

36 mAA was defined as depression of 2 of the 3 blood counts: absolute neutrophil count 1200/mm3 or less

37 10, respectively) achieved normalization of blood counts after six (57% and 90%, respectively) and 1

38 e attributed to intrinsic variation in white blood count among the donors.

39 investigate the prevalence of low peripheral blood counts among HCV-infected adults in the United Sta

40 Parameters of blood count analysis (elevated leukocyte and platelet co

41 Complete blood count analysis demonstrated that disruption of int

42 5.1% of subjects (78 of 1520) with a normal blood count and 13.9% (309 of 2228) with lymphocytosis.

43 who were 62 to 80 years of age with a normal blood count and 2228 subjects with lymphocytosis (>4000

44 outine laboratory values, including complete blood count and basic metabolic panels, were normal.

45 Her complete blood count and basic metabolic profile were unremarkabl

46 To assess toxicity, full blood count and biochemical parameters were determined.

47 High fever, viraemia and abnormalities in blood count and blood chemistry were evident in many ani

48 An electrocardiogram was obtained and blood count and blood chemistry were measured up to 12 w

49 llopurinol prescription, and QI 3 = complete blood count and creatine kinase check every 6 months for

50 Laboratory test results, including complete blood count and electrolyte, creatinine, creatine phosph

51 After adjustment for sex, age, and white blood count and excluding chemotherapy-treated patients

52 Patient underwent full blood count and haemoglobin electrophoresis to exclude t

53 d individuals (aged >45 years, with a normal blood count and no history of cancer) in the UK.

54 oppositely associated with presenting white blood count and PML-RARalpha type: ACA, low, L-isoform;

55 K1/2 inhibitor ruxolitinib lowered the white blood count and reduced spleen weight.

56 Routine biochemistry (full blood count and renal function) results were normal.

57 All DS neonates had multiple blood count and smear abnormalities.

58 risk of ML-DS, we suggest GATA1 mutation and blood count and smear analyses should be performed in DS

59 nction cluster, vital-sign cluster, complete blood count and sodium clusters.

60 Newborns frequently exhibit abnormal blood counts and a clonal preleukemia.

61 In vivo blood counts and animal weights were consistent with min

62 Peripheral blood counts and bone marrow histology were used to asse

63 1,2-HOPO-Davisil did not change complete blood counts and common blood biochemistry.

64 Complete blood counts and comparison of means and the proportion

65 dividuals age 18 or older who had peripheral blood counts and data on HCV infection.

66 7F) expression displayed marked increases in blood counts and developed phenotypes that closely resem

67 is study we assess the accuracy of capillary blood counts and evaluate the potential of a miniaturize

68 Complete blood counts and flow cytometric analyses were performed

69 However, their long-term effects on blood counts and hematopoiesis are poorly understood.

70 d during outpatient care, including complete blood counts and hepatic and renal function tests.

71 Whereas initial high blood counts and high lactate dehydrogenase as an indica

72 Blood counts and immune cell function are preserved foll

73 munodeficiency had peripheral blood complete blood counts and lymphocyte subsets assayed in a single

74 rinostat treatment normalized the peripheral blood counts and markedly reduced splenomegaly in Jak2V6

75 on revealed normal complete and differential blood counts and normal serum chemistry, including a nor

76 was well tolerated with complete recovery of blood counts and reversible nonhematologic toxicities at

77 These were correlated to blood counts and smears in a subset of patients.

78 we prospectively analyzed clinical findings, blood counts and smears, and GATA1 mutation status in 20

79 essment included abdominal ultrasound, whole-blood counts and smears, determinations of plasma immuno

80 with marked improvement in peripheral white blood counts and splenomegaly.

81 ve to stem-cell transplantation and improves blood counts and survival.

82 n the UBE2T loci displayed normal peripheral blood counts and UBE2T protein levels in B-lymphoblast c

83 titis C virus (HCV) RNA levels, and complete blood counts and underwent liver biopsy at the completio

84 eters, including fever, heart rate, complete blood count, and bacteremia; and evaluated the PCR assay

85 autopsy, organ histology and immunostaining, blood count, and chemical profile.

86 jects had undergone a phlebotomy, a complete blood count, and cognitive and dietary assessments.

87 ion values of high MELD, low MAP, high white blood count, and low albumin.

88 medical tests (electrocardiography, complete blood count, and measurement of serum levels of electrol

89 od cell traits hemoglobin, hematocrit, white blood count, and platelet count.

90 demographics, CVL types and insertion dates, blood counts, and complications were reviewed through we

91 Weight measurement, complete blood counts, and histopathology analysis were performed

92 -STAT signaling, normalization of peripheral blood counts, and improved survival in MPN models at dos

93 ulmonary cytokines, lung histology, complete blood counts, and intestinal proliferation were similar

94 ing skin score, liver function tests (LFTs), blood counts, and lung function tests.

95 nia, which occurred regardless of pretherapy blood counts, and persisted an average of 2 months.

96 r erythroid engraftment and normalization of blood counts, and persistence in some without continued

97 etry), conventional coagulation tests, whole blood counts, and platelet flow cytometry were performed

98 evated plasma chromogranin A level, baseline blood counts, and renal function.

99 tions of ISATX247 and cyclosporine, complete blood counts, and serum chemistry profiles were performe

100 g patients evaluable at 12 months had normal blood counts, and seven (78%) of nine patients were tran

101 2499 patients were smokers and had available blood counts, and so were stratified by mean blood eosin

102 laboratory test results, including complete blood count; and liver function test results were normal

103 laboratory test results, including complete blood count; and liver function test results were normal

104 Unless earlier blood counts are available, and they often are not, the

105 Peripheral blood counts are not reliable in characterising airway i

106 re assessed every 3-6 months on the basis of blood counts as defined by the European LeukemiaNet crit

107 , HBsAg level, liver function test, complete blood count, aspartate aminotransferase-to-platelet rati

108 teria (86% vs 40% at 5 years; P<.001) and by blood counts at 3 months (reticulocyte count or platelet

109 g variables, no association was seen between blood counts at diagnosis and future complications.

110 y in the myeloid lineage and did not require blood count (BC) or bone marrow (BM) biopsy for MDS conf

111 evidence of changes in body weight, complete blood count, blood chemistry profile, cardiac contractil

112 tions for infection (urine culture, complete blood count, blood culture, and wound culture) in the 7

113 ution of the constituent materials, complete blood counts, blood chemistry and magnetic resonance ima

114 Further work-up consisted of a complete blood count, bone marrow biopsy, and immunohistochemical

115 e, race, FLT3 subtype, cytogenetic risk, and blood counts but not with respect to sex (51.7% in the m

116 Eighty-eight percent of patients with normal blood counts, but with headaches, lethargy, or abdominal

117 Complete blood count, C-reactive protein level, sedimentation rat

118 ere we investigate whether full differential blood counts can predict susceptibility to clinical mala

119 Risk Score (IMRS), composed of the complete blood count (CBC) and basic metabolic profile (BMP), pre

120 Several parameters of preoperative complete blood count (CBC) and inflammation-associated blood cell

121 om a 3-year period, with associated complete blood count (CBC) and liver function test results, were

122 Hematological analysis, via a complete blood count (CBC) and microscopy, is critical for screen

123 Complete Blood Count (CBC) is a collection of the most commonly r

124 The complete blood count (CBC) provides a high-level assessment of a

125 ocyte-colony-forming unit (CFU-GM), complete blood count (CBC), and donor chimerism at various days a

126 ion, comprehensive blood chemistry, complete blood count (CBC), and urinalysis.

127 Blood analyses included a complete blood count (CBC), sequential multiple analyzer 24 (SMA

128 Complete blood count (CBC), serum chemistries, bile acid profile,

129 nts received anemia education and a complete blood count (CBC).

130 Clinical observations and complete blood counts (CBC) were performed.

131 ate these differences, we evaluated complete blood counts (CBC), antibody binding of RBCs, T cell num

132 physician-ordered blood culture and complete blood count [CBC]), and 102 controls (healthy blood dono

133 Complete blood counts (CBCs) were obtained on the day of injectio

134 Body weights, complete blood counts (CBCs), and blood pressure were obtained to

135 Complete blood count changes, including new cell activation param

136 The use of complete blood counts, chemistry panels, bone scans, chest radiog

137 two HCV antigen tests and US$22 for two full blood count/clinical chemistry tests.

138 s of genotyping, HCV antigen tests plus full blood count/clinical chemistry tests.

139 d a significantly greater effect in reducing blood counts compared to bone marrow counts (P < 0.001).

140 ismatched allogeneic donor doubled the white blood counts compared with recipients of one single unit

141 Declining blood counts correlated with marked expansion and activa

142 artial haematological recovery of peripheral blood counts (CRh) within the first two cycles.

143 achieved a CR with insufficient recovery of blood counts (CRi).

144 e complexes, complement activation, complete blood counts, cytokine/chemokine, and gene expression ch

145 Blood count data indicated that this effect was not acco

146 Incorporation of blood count data into the model accounted for the discre

147 ions with dengue virus, one missing complete blood count data) and two participants who were non-Zika

148 ts who were non-Zika cases (missing complete blood count data) were excluded from analysis.

149 FN-gamma was present in T cells prior to the blood count decline in 13, and 12 responded to reinstitu

150 Differential blood counts demonstrated up to an 80% drop in lymphocyt

151 utive in all patients studied, regardless of blood count, disease stage, or treatment status.

152 isorders that are characterized by decreased blood counts due to ineffective hematopoiesis.

153 Laboratory studies included normal blood counts, electrolytes, and renal and liver function

154 regardless of the type of uveitis (complete blood count, erythrocyte sedimentation rate, C-reactive

155 lower, incomplete, and transient, with whole blood counts falling to 7% to 38% injected dose by about

156 cells used for hematopoietic rescue restore blood counts faster than allogeneic bone marrow, without

157 ue for use in diagnostic testing of the full blood count (FBC) at the point-of-care (POC), for which

158 aimed to assess the predictive role of full blood count (FBC) parameters in prognosis of heart failu

159 Further testing was reduced for full blood counts (FBC) (RR 0.80, 95% CI 0.69-0.92 I2 = 0%),

160 Additional assessments included blood counts, fetal haemoglobin concentration, chemistry

161 BM stem and progenitor cells and of complete blood counts following irradiation.

162 Complete remission was defined as normal blood count for age and sex.

163 V-based plasmids increased circulating white blood counts for at least 2 months following a single CL

164 cal response was defined as normalisation of blood counts (for patients with essential thrombocythaem

165 The changes in blood counts from lentivirus injection were associated w

166 Significantly, peripheral blood counts from TgPKR mice decrease with age in associ

167 Full blood count, glomerular filtration rate, and liver funct

168 e patients with robust near-normalization of blood counts had drug discontinued at a median of 28.5 m

169 Blood count, hematocrit, hemoglobin concentration and me

170 nt underwent serial measurements of complete blood count, hepatic profile, coagulation profiles, and

171 ot correlate with age, gender, infection, or blood counts; however, 3 correlated with specific cytogn

172 Blood count improvements meeting the International Worki

173 The increase of white blood count in 28 patients was lower after recurrent MI

174 hes have centered on improving the patient's blood counts in a palliative manner.

175 ependence or complete recovery of peripheral blood counts in a proportion of patients.

176 scular complications and 21 887 longitudinal blood counts in a prospective, multicenter cohort of 776

177 Vemurafenib treatment improved blood counts in all patients, with platelets, neutrophil

178 , led to clinically significant increases in blood counts in almost half the patients.

179 care, oxymetholone, by improving peripheral blood counts in Fancd2(-/-) mice significantly faster.

180 rolonged observation showed normalization of blood counts in most JAK2(V617F) mice, suggesting that t

181 somatic ASXL1 mutations contribute to lower blood counts in otherwise asymptomatic individuals.

182 ical findings (signs, symptoms, and complete blood counts) in both Zika cases and non-Zika cases.

183 Low blood count is a fundamental disease state and is often

184 Not the high blood count itself, but complications such as leukostasi

185 immunized macaques, as indicated by complete blood counts, leukocyte differentials and hepatic and re

186 Complete blood counts, liver and renal function test results, and

187 A full blood count; liver function test; and measurements of ur

188 -specific likelihood values for the complete blood count may determine risk of infection.

189 c microcytic anemia pattern seen in complete blood count (MCV 70.2 fl, MCH 21.4 pg).

190 r of patients with various abnormal complete blood count measurements, and location-specific hospital

191 aptively identified using recurrent complete blood count measurements, which sufficiently constrain t

192 in patients with available baseline complete blood counts (n=3717).

193 to other established blood tests (e.g. White Blood Count, Neutrophils or C - reactive protein) in pre

194 For the complete blood count, no significant differences were observed be

195 no significant changes in body weight, cell blood count, nor plasma biomarker indices.

196 i [CR with incomplete recovery of peripheral blood counts]) occurred in 30 of 111 (27%) GO recipients

197 The peripheral blood count of CD14(high)/CD16(+) monocytes correlated w

198 efficiency, in vitro stability, or complete blood count of leukocytes labeled with stabilized 99mTc-

199 Complete blood counts of all three of our patients revealed red b

200 r:Star-mPEG/antimiR-145 with serial complete blood counts of leukocytes and serum metabolic panels, g

201 Blood counts of patients with dyskeratosis congenita or

202 pletion, marrow cellularities and peripheral blood counts of the remaining young and elderly dogs wer

203 ent age, weight, pre- and postoperative full blood counts, operating time, estimated blood loss, conv

204 Mutations in DNMT3A had no impact on blood counts or indices.

205 oints were clinically significant changes in blood counts or transfusion independence.

206 mor growth without any change in the weight, blood counts, or chemistries.

207 a, liver and kidney function tests, complete blood counts, or pathology of major organs are observed

208 s (P < .005), and a failure to normalize the blood count (P = .001).

209 en missense variants of LCT and higher white blood count (p = 4 x 10(-13)).

210 ificantly older (P = .0001), had lower white blood counts (P = .0006), and lower percentages of BM bl

211 agnosis, non-type A patients had lower white blood counts (P = .007), and more often trisomies of chr

212 dictive of the clinical course than complete-blood-count parameters.

213 luded people 30 years or older with complete blood counts performed in usual clinical care and no his

214 ividuals in the cohort, 154,179 had complete blood counts performed under acute conditions and 621,05

215 Initial blood count (performed at an outside hospital) showed el

216 Thus, despite restoration of peripheral blood count, phagocytic defects in the AMs of BMT mice p

217 Complete blood counts, plasma interleukin-6 (IL-6) levels, and bo

218 t's or May-Grunwald-Giemsa, determination of blood counts, platelet size and appearance.

219 fect hematopoiesis as determined by complete blood count profiles.

220 Brodin et al. show that the heritability of blood counts rapidly decreases with age for the lymphoid

221 t count (CRp; 14%), and 5 CR with incomplete blood count recovery (14%).

222 ses and 2 complete responses with incomplete blood count recovery (all with AML treated at/below MTD)

223 est doses achieved CR and CR with incomplete blood count recovery (CRi) at day 28.

224 a complete remission (CR)/CR with incomplete blood count recovery (CRi) or did not progress after 2 c

225 sion (CR), whereas 11 had CR with incomplete blood count recovery (CRi).

226 d complete remission (CR)/CR with incomplete blood count recovery (median time to first response, 1.4

227 ssion and complete remission with incomplete blood count recovery rate (CR + CRi) of 46%.

228 The mean time to blood count recovery was 12 mo after the termination of

229 ut prior HMA exposure, CR/CR with incomplete blood count recovery was achieved in 62%, median DOR was

230 d complete remission (with or without normal blood count recovery) and remission with undetectable mi

231 ssion and complete remission with incomplete blood count recovery) was higher for LDAC + volasertib v

232 omplete remission with incomplete peripheral blood count recovery), and 18% died within 30 days.

233 sion [CR] plus CR with incomplete peripheral blood count recovery), disease-free survival (DFS), dura

234 ogenetic risk, secondary disease, incomplete blood count recovery, and abnormal karyotype pre-HCT, MR

235 ission or complete remission with incomplete blood count recovery, and if the 30 day death rate was 2

236 collected on or closest to the first date of blood count recovery, and MRD was determined by 10-color

237 AML) had complete remission with incomplete blood count recovery, and one (FLT3 wild-type AML) had p

238 eved a morphologic remission with incomplete blood count recovery.

239 asily derived from routine full differential blood counts, reflects an individual's capacity to mount

240 consistently, associated with elevations in blood counts relative to mutation-negative myeloprolifer

241 In conclusion, physical examination and blood count remain the methods of choice for staging and

242 influence of HCV infection on the peripheral blood count remains unknown.

243 Complete blood counts, renal and liver function assessments, prev

244 ine transaminase (ALT), creatinine, and full blood count revealed moderate ALT elevation in <2.5% of

245 A basic serum chemistry test and complete blood count revealed no abnormal findings.

246 Analysis of complete blood counts revealed a median hemoglobin level of 10.6

247 Peripheral blood counts revealed a profound reticulocytosis and thr

248 ipients were followed up with daily complete blood count, scheduled chest radiographs, and biopsies.

249 Blood samples were analyzed for complete blood count, serum chemistry profile, level of alanine a

250 mination, routine laboratory tests (complete blood count, serum creatinine level), urine albumin/crea

251 a) the tests to be obtained daily: complete blood count, serum electrolytes, urea nitrogen, creatini

252 His blood count shows signs of mild iron deficiency anemia.

253 th clinical periodontal parameters, complete blood count, smoking status, and age.

254 They are monitored clinically by complete blood counts, specifically with measurements of platelet

255 Combination treatment improved blood counts, spleen weights, and reduced bone marrow fi

256 e improved survival was unclear, as complete blood counts, splenic and marrow cellularity, numbers an

257 platelets (PLTs) and megakaryocytes (MKs) on blood counts, stem/progenitor cells, and Jak-Stat signal

258 ra-phenylenediamine staining, and a complete blood count system was used to measure the number of ery

259 A fully operational microfluidic blood-counting system for preclinical pharmacokinetic st

260 id neoplasms, as these cells reverse the low blood counts that cause morbidity and death.

261 ission of the AML, in the presence of normal blood counts, the hematopoiesis stably maintained the ho

262 transient and mild suppression of peripheral blood counts, the numbers of individual stem/progenitor

263 ible/negative (< 1%) yield included complete blood counts (therapy-related leukemia), dipstick urinal

264 with 30% of the mice showing elevated white blood counts, they all died of T-cell lymphoma, which wa

265 rent toxicity, and animals maintained normal blood counts throughout.

266 BTNPs showed better restoration of complete blood count to normal level, and significantly longer me

267 The ratio of individual blood counts to bone marrow counts was 10 (IQR, 2.3 to 9

268 Complete blood counts to measure total eosinophils, fractional ex

269 en with SCA with a neurologic exam, complete blood count, transcranial Doppler ultrasound (TCD), meas

270 Evaluation of bone marrow, blood counts, transfusions, progression, and survival fo

271 t asymptomatic mutation carriers have normal blood counts until malignancy develops.

272 ted microfluidic system that performs a full blood count using impedance analysis.

273 We then examined complete blood count values in the electronic health records (EHR

274 diagnosis, the median CD3(+)CD4(+) absolute blood count was 480.5 cells/microL (range, 165-632 cells

275 In all four patients, a normal blood count was achieved within four weeks after treatme

276 A complete blood count was carried out in all UK Biobank participan

277 nd 3 h after preparation, whereas a complete blood count was obtained at 3 h after preparation.

278 White blood count (WBC), C-reactive protein (CRP) and PCT leve

279 d scan (USS), C - reactive protein and White blood counts (WCC) in aiding early diagnosis in children

280 e comprehensive metabolic panel and complete blood count were normal throughout and after the pregnan

281 evelopment of bacteremia, and mean bacterial blood counts were all significantly higher in the rabbit

282 Histology and complete blood counts were analyzed in naive C57BL/6 mice that we

283 Complete blood counts were available for four patients, revealing

284 Blood counts were compared to gold-standard automated cl

285 Serial blood counts were measured, bronchoalveolar lavage (BAL)

286 Tumor size, survival, body weight, and blood counts were monitored for efficacy and toxicity of

287 Liver chemistries and complete blood counts were monitored, and patients were encourage

288 l signs of dyskeratosis congenita, and their blood counts were nearly normal, but all had severely sh

289 Complete blood counts were normal or near normal in all patients

290 y of underlying malignancy, and the complete blood counts were normal.

291 l transplantation, peripheral blood complete blood counts were performed and examined for polymorphon

292 Complete blood counts were performed every 2 years.

293 , or 10 years of age or older with any white blood count) were enrolled.

294 renal function, liver function, and complete blood count, were within normal limits.

295 ood transfusion rate, school attendance, and blood count-were analyzed by intention-to-treat analysis

296 baseline and at study completion; a complete blood count with differential and comprehensive metaboli

297 Complete blood count with differential, serology screen (includin

298 gy analyzer during performance of a complete blood count with differential.

299 HP (full blood count with indices using automated analyzer and pe

300 ial (CRh) hematologic recovery of peripheral blood counts within the first 2 cycles.